BDD Pharma opens brand new GMP manufacturing facility following £2m in funding
Media release
8 April 2025
BDD Pharma opens brand new GMP manufacturing facility following £2m in funding
• New facility will provide cost-effective manufacturing and clinical testing for pharma and contract research organisations of all sizes.
• Significant increase in technical positions at BDD helping further strengthen Scotland’s life sciences workforce
Glasgow, Scotland, 8 April 2025 – Leading contract research company BDD has opened its new 122m² GMP manufacturing facility at BioCity near Glasgow, following a successful
inspection by the Medicines and Healthcare products Regulatory Authority (MHRA) in March 2025.
Two years in the making, the development of the state-of-the-art facility was facilitated by a funding round of £2 million from existing investors led by the world’s longest running angel
investment syndicate, Archangels, with Scottish Enterprise and new investor, British Business Bank.
Constructed by cleanroom specialists Guardtech Group, the GMP facility significantly expands BDD’s manufacturing capabilities and clinical testing services, supporting research and
development for small and medium-sized pharmaceutical companies. It also underpins BDD’s lean clinical development approach, enabling rapid clinical readouts while maintaining
unwavering quality in each project delivered.
Based in Scotland, BDD is a privately owned company, whose mission is to speed up the development of new medicines for the improvement of patient lives by combining rapid early
clinical testing with an unrivalled knowledge of how dosage forms work in the body.
Stephen Clarke, Head of Quality at BDD, commented: “This new additional facility provides a wonderful opportunity to generate even quicker reliable data on the safety and effectiveness of
these newly developed medicines. That in turn will lead to new medicines getting into patients quicker and so improve patient health sooner, which benefits all of society. “The outcome of the recent UK Government Inspection provided a high level of independent confidence that we are doing all the correct things, in the correct way, consistently.”
Sarah Hardy, Director and Head of New Investments at Archangels, added: “The investment in the new facility strengthens BDDs ability to offer end to end services to meet the growing
market demand and dovetails the company’s clinical expansion. “BDD’s uniquely supports pharmaceutical companies of any size that need to act quickly or
accelerate plans enabling them to navigate the complex path of getting new therapies to patients.”
To find out more about BDD Pharma, please visit: https://www.bddpharma.com
To find out more about Archangels, please visit: https://archangelsonline.com
ENDS
Issued by Frame on behalf of Archangels.
For further information, please contact:
Paddy.Baxter@framecreates.co.uk / 07387 090 070
About Archangels
Founded in 1992, Archangels is a leading business angel syndicate investing in early-stage
Scottish life sciences and technology companies. Archangels comprises around 120 members
and an eleven-strong board and executive team. For further information on Archangels, visit:
www.archangelsonline.com.
About BDD
BDD has over 25 years’ experience in pharmaceutical development, manufacturing, and clinical
testing, BDD provides an integrated approach to streamline the path to Phase I clinical data. By
reducing inefficiencies, BDD helps accelerate early-stage development. For more information,
visit: www.bddpharma.com.
About Scottish Enterprise
Scottish Enterprise (SE) is Scotland’s national economic development agency and a non
departmental public body of the Scottish Government. It supports businesses to innovate and scale to
transform the Scottish economy by focusing on new market opportunities through targeted
investment, innovation and internationalisation. Follow us on X (formerly Twitter) and LinkedIn.
